Daniel J Buzard

USPTO Granted Patents = 40 (Patent Applications = 19)

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 14 (Patent Applications = 23)

Average Co-Inventor Count = 4.6

ph-index = 9

Forward Citations = 208(Granted Patents)

Company Filing History:

12 out of 216

Arena Pharmaceuticals, Inc.

patents

11 out of 2,076

Janssen Pharmaceutica Nv

Abide Therapeutics, Inc.

patents

5. 3 out of 12

Lundbeck La Jolla Research Center, Inc.

patents

6. 1 out of 1

Vidya Therapeutics, Inc.

patent

Years Active: 2007-2025

Loading Chart...

40 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12448363 - Kinase inhibitors (2025-10-21),

2. 12378219 - Crystalline forms of a MAGL inhibitor (2025-08-05),

3. 12152029 - Crystalline forms of a MAGL inhibitor (2024-11-26),

4. 11691975 - MAGL inhibitors (2023-07-04),

5. 11674163 - Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof (2023-06-13),

6. 11555015 - Compounds useful in the treatment of autoimmune and inflammatory disorders (2023-01-17),

7. 11434222 - MAGL inhibitors (2022-09-06),

8. 11332453 - MAGL inhibitors (2022-05-17),

9. 11214557 - MAGL inhibitors (2022-01-04),

10. 11161856 - Spirocycle compounds and methods of making and using same (2021-11-02),

11. 11149292 - Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof (2021-10-19),

12. 11149037 - Pyrazole MAGL inhibitors (2021-10-19),

13. 11142526 - Spirocycle compounds and methods of making and using same (2021-10-12),

14. 11059822 - MAGL inhibitors (2021-07-13),

15. 10899737 - Piperazine carbamates and methods of making and using same (2021-01-26),

Title: Daniel J Buzard: Innovating in Drug Development

Introduction

Daniel J Buzard is a notable inventor based in San Diego, CA, who has made significant contributions to the field of pharmaceuticals through his 38 patents. His work primarily focuses on developing innovative compounds that play a crucial role in pain management and other medical applications.

Latest Patents

Among his latest patents, one that stands out is related to crystalline forms of a MAGL inhibitor. This invention describes new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof. Another significant patent revolves around spirocyclic and fused bicyclic carbamates as MAGL inhibitors. These compounds and their pharmaceutical compositions serve as valuable modulators of MAGL, demonstrating efficacy in the treatment of pain.

Career Highlights

Daniel has had an impactful career, working with leading pharmaceutical companies such as Arena Pharmaceuticals, Inc. and Janssen Pharmaceutica NV. His role in these organizations has allowed him to contribute extensively to research and development, particularly in drug formulation and delivery.

Collaborations

Throughout his career, Daniel has collaborated with esteemed colleagues in the field, including Cheryl A Grice and Michael B Shaghafi. These partnerships have undoubtedly enhanced the innovative capacity of his projects and led to the successful development of various pharmaceutical products.

Conclusion

Daniel J Buzard continues to be a driving force in the field of pharmaceuticals, exemplified by his impressive portfolio of patents. His contributions, particularly in the development of MAGL inhibitors, are paving the way for improved treatments for pain and showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.